For anyone in Secui searching for CJC-1295, the first thing to know is that this compound is available only through an online research supply market. The practical takeaway for Secui researchers: sourcing CJC-1295 depends entirely on vendor quality evaluation, not geography — and the evaluation methodology is the same regardless of where you are. The primary quality indicators for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a lot-traced Certificate of Analysis. This guide walks Secui researchers through that evaluation process and explains the signals that distinguish quality CJC-1295 suppliers.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Secui comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate CJC-1295 Vendors
Before looking at individual vendors, establish a quality benchmark — so you can tell whether a COA is complete and credible. When reviewing a CJC-1295 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are below the threshold for research use. Strong quality indicators beyond COA quality: multi-year operating history, customer service that can discuss analytical methods, and temperature-appropriate packaging with desiccant. For Secui researchers making a first CJC-1295 purchase: work through this evaluation framework first, begin with a small order, and confirm the COA batch number matches your received product before use.
Order CJC-1295 — ships to Secui
COA-verified · International tracking · Research grade
CJC-1295 is sold for research purposes only and is not approved for human use by the FDA or equivalent agencies worldwide — all information here is educational. Temperature excursions — even short periods above −20°C — can compromise product integrity without any obvious sign; always verify cold chain was maintained during shipping. Endotoxin testing in the CJC-1295 COA is non-negotiable — gram-negative bacterial endotoxins can trigger severe inflammatory responses at trace quantities, and no cost saving makes omitting this acceptable. Protocol documentation — recording exactly what was used, when, and how — is a fundamental research principle that makes anomalous results interpretable.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
